ROMARK INITIATES PHASE 3 CLINICAL TRIALS OF NT-300 FOR COVID-19

2020-06-25T16:45:53-04:00June 24th, 2020|Categories: COVID-19 Posts, Press Releases|

Clinical Development Program for NT-300 Includes Trials Addressing Prevention and Treatment of COVID-19 and Other Viral Respiratory Illnesses   TAMPA, Fla. – April 27, 2020 – Romark announced today it will initiate two clinical trials of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) for prevention of COVID-19 and other viral respiratory illnesses in high-risk